Clearbridge Investments LLC Acquires 95,619 Shares of Charles River Laboratories International, Inc. $CRL

Clearbridge Investments LLC raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 23.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 511,618 shares of the medical research company’s stock after purchasing an additional 95,619 shares during the period. Clearbridge Investments LLC’s holdings in Charles River Laboratories International were worth $102,058,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tema Etfs LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at approximately $26,000. Rothschild Investment LLC boosted its stake in Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in Charles River Laboratories International in the third quarter valued at approximately $31,000. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at approximately $42,000. Finally, Activest Wealth Management boosted its stake in Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Up 3.0%

CRL opened at $186.75 on Tuesday. The firm’s fifty day moving average is $171.80 and its two-hundred day moving average is $181.87. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The firm has a market cap of $9.00 billion, a PE ratio of -49.67, a price-to-earnings-growth ratio of 2.07 and a beta of 1.46. Charles River Laboratories International, Inc. has a twelve month low of $143.06 and a twelve month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the business posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their price objective for the company from $167.00 to $219.00 in a research note on Friday, May 29th. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.